FDA Approved: PREVYMIS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for PREVYMIS (letermovir) from Merck Sharp & Dohme LLC, expanding regulatory authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

SUPPL AP for PREVYMIS (LETERMOVIR)